PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Zeng, Jian
Wang, Guoqiang
Yan, Zhengqing
Zheng, Hao
Li, Jianqiang
Tao, Feng
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
[3] Wen Zhou Med Univ, Lishui Peoples Hosp, Dept Resp Med, Affiliated Hosp 6, Lishui, Peoples R China
[4] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[5] Jiaxing Univ, Dept Resp Med, Affiliated Hosp, Jiaxing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15112
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
    Miura, Yosuke
    Kasahara, Norimitsu
    Sunaga, Noriaki
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S628 - S632
  • [42] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
    Abdayem, Pamela
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
  • [43] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [44] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
    Kolesnik, O. P.
    Mykhailychenko, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
  • [45] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Zhenbin Qiu
    Zihao Chen
    Chao Zhang
    Wenzhao Zhong
    Experimental Hematology & Oncology, 8
  • [46] Early shifts in immune cell subsets to predict response to immune checkpoint blockade in non-small cell lung cancer (NSCLC).
    Rosner, Samuel
    Forde, Patrick M.
    Naidoo, Jarushka
    Marrone, Kristen
    Reuss, Joshua E.
    Feliciano, Josephine Louella
    Levy, Benjamin Philip
    Hann, Christine L.
    Velculescu, Victor E.
    Brahmer, Julie R.
    Anagnostou, Valsamo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [47] An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
    Genova, C.
    Coco, S.
    Rossi, G.
    Longo, L.
    Chiorino, G.
    Ostano, P.
    Guana, F.
    Metro, G.
    Baglivo, S.
    Ludovini, V.
    Vanni, I.
    Rijavec, E.
    Biello, F.
    Dal Bello, M. G.
    Tagliamento, M.
    Dellepiane, C.
    Alama, A.
    Bennicelli, E.
    Chiari, R.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S825 - S826
  • [48] iSEND Model as a Predictor of Efficacy in Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer: Fukushima Cohort
    Okabe, N.
    Mine, H.
    Takagi, H.
    Watanabe, M.
    Muto, S.
    Hasegawa, T.
    Shio, Y.
    Park, W.
    Lopes, G.
    Suzuki, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S935 - S935
  • [49] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer Response
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao, V
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 477 - 478
  • [50] Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
    Lin, Anqi
    Wei, Ting
    Meng, Hui
    Luo, Peng
    Zhang, Jian
    MOLECULAR CANCER, 2019, 18 (01)
12345